摘要
目的：了解笔者所在地区男性泌尿生殖道支原体的感染及耐药的变化趋势,为有效防治支原体提供参考依据。方法：对笔者所在医院2008-2012年男性泌尿生殖道支原体分离培养鉴定及药敏试验的资料进行回顾性分析,统计感染率及耐药性。结果：2008-2012年男性泌尿生殖道支原体的感染率分别为31.0%、34.7%、33.0%、33.9%、33.5%,各年度感染率的差异无统计学意义（P〉0.05）,其中以单一解脲支原体（Uu）感染为主,其次为Uu＋人型支原体（Mh）混合感染,单一Mh感染最少;Uu＋Mh混合感染对大部分抗菌药物的耐药率较高,处于50%~90%,而单一Uu感染则对大部分抗菌药物的耐药率处于10%～40%。结论：男性泌尿生殖道感染中有三分之一为支原体感染,应加强防控;不同分型的支原体对抗菌药物的耐药性不同,在治疗中应根据药敏结果选药,以控制耐药性的产生。
Objective： To Understand the region＇ s male urogenital mycoplasma infection and drug trends, to provide a reference for the effective prevention and treatment of mycoplasma. Method： Retrospectively analysed infection rates and resistance hospital 2008-2012 male urogenital mycoplasma isolation and culture identification and susceptibility testing. Result： The male urogenital mycoplasma infection rates in 2008-2012 were 31.0%, 34.7%, 33.0%, 33.9%, 33.5%, the annual infection rates showed no significant difference （ P〉0.05 ）, in which a single Uu infection, followed by Uu ＋ Mh mixed infection least single Mh infection; Uu ＋ Mh mixed infection of most of the antimicrobial resistance rates higher, and in 50% to 90%, while the single Uu infection of most of the antimicrobial resistance. The drug rate was 10% to 40%. Conclusion： Male urogenital tract infection in one-third of mycoplasma infection, should strengthen the prevention and control; different type of mycoplasma antimicrobial resistance, in the treatment of drug selection should be based on susceptibility results, in order to control the resistance generation.
出处
《中国医学创新》
CAS
2013年第18期106-108,共3页
Medical Innovation of China
关键词
男性
泌尿生殖道
支原体
感染
耐药性
Male
Genitourinary tract
Mycoplasma
Infection
Resistance
